We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 26

Bio-Rad agrees to pay $55 million to resolve SEC bribery charges
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

A California-based clinical diagnostic and life science research company has reportedly agreed to pay $55 million to resolve U.S. Securities and


NanoString seeks $55 million to advance breast cancer test
  • Shook Hardy & Bacon LLP
  • USA
  • January 30 2014

NanoString Technologies, Inc., which develops life-science research tools, including analytical systems used by cancer researchers to study the


Biotech raises $57.4 million in IPO
  • Shook Hardy & Bacon LLP
  • USA
  • January 30 2014

GlycoMimetics, Inc., a biotechology company focusing on the development of treatments for blood cancers and inflammatory diseases, has closed its


Cancer biotech seeks $69 million in IPO
  • Shook Hardy & Bacon LLP
  • USA
  • January 9 2014

Dicerna Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission indicating its intent to raise up


Biotech Genocea Biosciences files IPO to fund vaccine development
  • Shook Hardy & Bacon LLP
  • USA
  • January 9 2014

Genocea Biosciences, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission relating to a proposed initial public


Can biotech investor confidence continue?
  • Shook Hardy & Bacon LLP
  • USA
  • December 12 2013

Nature Biotechnology Business Editor Brady Huggett recently examined the 2013 surge in biotechnology initial public offerings (IPOs) and considers


Boston region surges ahead in biotech IPOs
  • Shook Hardy & Bacon LLP
  • USA
  • November 21 2013

According to an analysis of initial public offering (IPO) data from 2013, xconomy's National Biotech Editor Luke Timmerman has concluded that Boston


Biopharmaceutical sets $150-million IPO terms
  • Shook Hardy & Bacon LLP
  • USA
  • November 21 2013

According to a news source, Redwood City, California-based Relypsa, Inc. seeks to raise $150 million by offering more than 7.87 million shares priced


Ultragenyx files with SEC to raise $86.25 million in IPO
  • Shook Hardy & Bacon LLP
  • USA
  • November 21 2013

Orphan disease drug developer Ultragenyx Pharmaceutical Inc. has filed a registration statement with the U.S. Securities and Exchange Commission


Aerie Pharmaceuticals seeks to raise $58 million in IPO to advance glaucoma drug
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Aerie Pharmaceuticals, Inc., has filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission outlining its plans to